Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Siemens Looks To CAD Firms In Light Of Digital Mammography Approval

This article was originally published in The Gray Sheet

Executive Summary

Siemens Medical Solutions will work with computer-aided detection system developers R2 and iCAD to link CAD to its Mammomat Novation full-field digital mammography system, PMA approved Aug. 20

You may also be interested in...



Global Diagnostics In Brief

Computer-aided detection: Siemens Medical's Mammomat Novation digital mammography system will integrate iCAD's Second Look Digital software as part of a three-year, worldwide licensing and distribution agreement. In a July 8 release, iCAD notes that U.S. product release is slated for 2005, following FDA approval of Mammomat, already cleared internationally. Last month, iCAD announced integration of its film-based analysis tool, Second Look 500M, with Confirma's MRI CAD to aid breast cancer detection....CADstream: Kirkland, Wash.-based Confirma launches CADstream 3.1 next-gen breast MRI analysis device July 8, following 510(k) clearance the previous day. The system includes SureLoc technology, allowing "automatic CAD-analysis and reporting of lesion location and calculations at the point of procedure," Confirma states. Other features include enhanced remote viewing and automatic reading capability within a 2-D region of interest. On July 1, GE Healthcare said it would distribute CADstream software to its global MRI customers...

Synthekine Joins Quest To Tame IL-2 In Cancer Therapies

First clinical data from Synthekine’s IL-2 candidate and that of rivals Medicenna were presented at the AACR, suggesting there’s life in the modality yet.

Swisse Supplements Take Bigger Slice Of Chinese Market

Australian-heritage Swisse grew its share of China's supplements market in 2023 by delivering tailored products to an increasingly health conscious population.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020811

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel